The Sarah Palin of Pharma: Former Novartis Executive in Japan Says Docs are Masters,...
As reported in the The Japan Times ("Diovan scandal traced to cozy doctor-drugmaker ties"):
The manipulation of clinical research data used to develop the blood...
FDA Wakes Up to Social Media’s Ability to Monitor Drug Adverse Events
Alec Gaffney reports that a recent FDA Notice of Solicitation (#1127679) calls for a "contractor capable of providing it with social media monitoring services...
Public Citizen Petitions FDA to Add a Black Box Warning to Low-T Drug Labeling
Public Citizen today called on the U.S. Food and Drug Administration (FDA) to immediately add a black box warning about the increased risks of...
Another Award I Nominate Me For: PM360’s Trailblazer Award
Regular Readers of Pharma Marketing Blog may know that I nominated myself for PMLiVE's Healthcare Communiquétor Award (see here). I now followup by nominating...
Do TV DTC Ads Overstate Rx Drug Risks? FDA May Make Changes that Put...
Balancing drug benefits (efficacy) against risks in direct-to-consumer (DTC) advertising has always been a contentious issue between pharma marketers and the FDA. About 40%...
Pharmalot R.I.P. Redux: Thoughts on Ed Silverman Joining Rupert Murdoch’s WSJ Blogosphere
In case you haven't heard, Ed Silverman -- former creator and writer of Pharmalot blog -- has joined The Wall Street Journal pharma/health team...
I Nominate Me for Healthcare Communiquétor: Who Seconds?
The Communiqué Awards 2014 are open for entry! "This award recognises outstanding personal achievement at a very senior level in healthcare communications. It is...
What the “Flappy Bird” Story Can Teach Pharma Game Developers
By now everyone has heard how the developer of "Flappy Bird" pulled the mobile game from the Apple and Google app stores because it...
Boehringer Ingelheim’s High Ranking in Social Media Patient Engagement vs. Shameful Real Life Anti-Patient...
Just because a pharma company gets kudos for engaging with and supporting patients via Social Media does not mean the company always has patients'...
A Pharma Marketing “Bait-and-Switch” Scheme: Sales Reps Disguised as Medical Science Liaisons
Celgene was accused of promoting its cancer drug Thalomid and related compound Revlimid for uses not approved by U.S. regulators in a newly unsealed...
